Surgery
Reinvented
Discover
The next breakthrough isn’t another drug,
it’s surgery.
When we talk about curing disease, the spotlight usually lands on biotech and pharmaceuticals. But surgery is still the most effective tool we have to treat—and often cure—cancer and other serious conditions.
It’s been overlooked, but shouldn’t be. At Current Surgical, we started with a simple but urgent question: What if surgery had the same investment, innovation, and imagination as the rest of medicine?
Surgery cures more solid tumors than drugs.
It remains the most effective way to remove cancer from the body—but while drugs and diagnostics get all the attention, surgery is still limited by outdated techniques, imprecise tools, and inconsistent access across systems.
Missing innovation in the operating room.
Biotech, pharma, and AI have transformed nearly every field in medicine, but surgery has been left behind. Most tools rely on century-old designs, forcing even the best surgeons to work without the precision modern care demands.
We started Current Surgical to fix this.
Driven by what’s possible—and frustrated by what’s still stuck in the past—we're building technology that gives surgeons digital precision, real-time visibility, and new ways to treat disease with less harm and more confidence.
Let’s start with cancer surgery
01
Most cancer patients face chemo and radiation—powerful, but sometimes blunt tools that hurt healthy cells, cause harsh side effects, and provide no real guarantee of a cure.
02
Common surgery can cure, but it’s invasive and risky. Many patients can’t undergo it, especially when tumors are near vital organs or their health is already compromised.
03
Dated tools limit precision. Surgeons work with centimeter-level accuracy, making it hard to fully remove tumors without damaging the organs and tissues that keep people alive.
What if we gave surgeons a 
new level of vision into the body?
With real-time digital imaging surgeons could spot tumors with greater accuracy—seeing what needs to be removed, and accurately avoiding what doesn’t.
What if we gave surgeons 
a new suite of precision tools?
Guided by imaging, surgeons could utilize micro-invasive tooling to treat tumors with focused microwave, being able to precisely treat what before was avoided.
See precisely.
Cure precisely.
Focused ultrasound and precision surgical instrumentation gives surgeons millimeter-level control for complete treatment of malignant tissue.
Machine Learning Copilot:
AI-driven algorithms process real-time imaging data, enhancing surgeon accuracy and confidence during complex procedures.
Ultrasound-Guided Precision:
Proprietary ultrasound sensors visualize tumors in 3D, enabling surgeons to navigate safely even in anatomically challenging cases.
Versatile Applications:
While the focus is on cancer treatment, this technology has potential uses in cardiac arrhythmias, chronic pain management, and beyond.
Reimagine surgery with Smart Needle Technology
Machine Learning Copilot:
AI-driven algorithms process real-time imaging data, enhancing surgeon accuracy and confidence during complex procedures.
Ultrasound-Guided Precision:
Proprietary ultrasound sensors visualize tumors in 3D, enabling surgeons to navigate safely even in anatomically challenging cases.
Versatile Applications:
While the focus is on cancer treatment, this technology has potential uses in cardiac arrhythmias, chronic pain management, and beyond.
Backed by Elite Investors
A growth path to health
Current Surgical targets early-stage solid tumors in areas where current surgical techniques fail. We calculate this to be a $X billion market subset within the larger oncology space.
While oncology remains our focus, our platform offers precision and adaptability to transform precision medicine across fields like cardiac arrhythmia, chronic pain, hypertension, and epilepsy.
2025
Oncology
2027
Cardiac Arrhythmia
2029
Chronic Pain
2030
Hypertension
2032
Epilepsy
The Future
Surgery will
evolve with us.
2025
Oncology
2027
Cardiac Arrhythmia
2029
Chronic Pain
2030
Hypertension
2032
Epilepsy
The Future
Surgery will
evolve with us.
The Future
Surgery will
evolve with us.
The Future
Surgery will
evolve with us.
2025
Oncology
2027
Cardiac Arrhythmia
2029
Chronic Pain
2030
Hypertension
2032
Epilepsy
The Future
Surgery will
evolve with us.
2025
Oncology
2027
Cardiac Arrhythmia
2029
Chronic Pain
2030
Hypertension
2032
Epilepsy
The Future
Surgery will
evolve with us.
The Future
Surgery will
evolve with us.
The Future
Surgery will
evolve with us.
Meet our team
Al Mashal
CEO / CoFounder
Chris Wagner
CoFounder
Heyuan Huang, Ph.D.
Deep Learning and Image Processing Scientist
Andrew Durette
Software Engineer
Fred Hamli18
Senior Consultant
Nicholas Pett
Mechanical Engineer
Julien Grondin
Principal Engineer
Join us!
See Openings
The Current Surgical team spans surgery, biomedical engineering, imaging, and robotics.
We’ve experienced firsthand the limitations of existing tools and are building what today’s OR actually needs.
With backgrounds at places like Johns Hopkins and MIT, we’ve developed FDA-cleared devices, led clinical trials, and built scalable medical systems—blending precision with practicality at every step.
News Room
September 28, 2022
Current Surgical Presents at the Inaugural Mayo Clinic Beahrs Surgical Innovation Summit / PR Newswire
View
July 12, 2023
Current Surgical Receives $400k Grant from NIH's National Cancer Institute to Develop Surgery Platform for Early-Stage Cancer / PR Newswire
View
June 21, 2023
Residents in Action – Current Surgical (BioBuzz) / PR Newswire
View
February 28, 2023
Medtech startup Current Surgical just landed a $3.2M seed round for its cancer treatment tech / Technical.ly
View
February 21, 2023
Current Surgical announces $3.2M seed raise, led by True Ventures / PR Newswire
View
February 21, 2023
Current Surgical is developing a ‘smart’ needle designed to treat cancerous tumors / TechCrunch
View
May 27, 2025

Medtech startup Current Surgical just landed a $3.2M seed round for its cancer treatment tech

Technical.ly

View
May 27, 2025

Residents in Action – Current Surgical

BioBuzz

View
May 27, 2025

Current Surgical Receives $400k Grant from NIH's National Cancer Institute to Develop Surgery Platform for Early-Stage Cancer

View